ERS Congress 2013 New Phase III data presented for first time demonstrate: tiotropium* Respimat ® significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS† treatment

ERS Congress 2013 New Phase III data presented for first time demonstrate: tiotropium* Respimat ® significantly improves lung function and provides sustained bronchodilation in asthma patients who remain symptomatic despite ICS† treatment
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news